

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Bell, et al.	Atty. Ref.:	18003
Appl. No.:	09/664,444	Group Art Unit:	1645
Filed:	September 18, 2000	Examiner:	Robert A. Zeman
Conf. No.:	4773	Customer No.:	31976
For:	ONCOLYTIC VIRUS		



* * * * *

December 23, 2003

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Examiner is directed to the documents listed on the enclosed Form PTO-1449. A copy of each listed document is enclosed.

This Statement is being filed in conjunction with a Request for Continued Examination for the above-mentioned application.

It is believed that no fee is required in connection with the filing of this Statement. If any fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Lewis J. Kreisler".

Lewis J. Kreisler
Reg. No. 38522
Attorney for Applicant(s)

930 Clopper Road
Gaithersburg, MD 20878
Phone: (240) 631-2500 x3276
Facsimile: (240) 683-3794



PTO/5B/085 (10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet 1 of 10	Attorney Docket Number	18003	

NON PATENT PUBLICATIONS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Kim, et al., "Replicating Viruses as Selective Cancer Therapeutics", Molecular Medicine Today, pages 519-527, December 1996.	
		Haide, et al., "Onyx-015, an E1B gene-inactivated adenovirus, causes tumor-specific cytotoxicity and antitumor efficacy that can be augmented by standard chemotherapeutic agents", Nature Medicine, Vol. 5, No. 6, pages 609-616, June 1999.	
		Duang, et al., "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy", Proc. Natl. Acad. Sci. USA, Vol. 93, pages 4543-4548, April 1996.	
		Kalte, "Regulation of the Interferon-Induced PKR: can viruses cope?", Trends in Microbiology, Vol. 3, No. 2, pages 75-78, February 1995.	
		Maneshwar, et al., "Low Infectivity of Vesicular Stomatitis Virus (VSV) Particles Released from Interferon-Treated cells is Related to Glycoprotein Deficiency", Biochemical and Biophysical Research Communications, Vol. 117, No. 1, pages 191-198, November 86-1986.	
		Chou, et al., "Association of a Mr 96,000 phosphoprotein with protein kinase PKR in cells exhibiting enhancing phosphorylation of translation complex virus 4", Proc. Natl. Acad. Sci. USA, Vol. 92, pages 10546-10550, November 1995.	
		Xu, et al., "Primary Leukemia Cells Resistant to α-Interferon in Vitro are Defective in the Activation of the DNA-Binding Factor Interferon-Stimulated Gene Factor 2", Blood, Vol. 84, No. 6, pages 1892-1899, September 1994.	
		Reinstein W, et al., "Human Cancer Cell Lines Express a Negative Transcriptional Regulator of the Interferon Regulatory Factor Family of DNA Binding Proteins", Molecular and Cellular Biology, Vol. 14, No. 2, pages 1477-1486, February 1994.	
		Symons, et al., "Vaccinia Virus Encodes a Soluble Type I Interferon Receptor of Novel Structure and Broad Species Specificity", Cell, Vol. 61, Pages 551-560, May 19, 1993.	
		Lingo, et al., "Interferon System Defects in Human Malignant Melanoma", Cancer Research, Vol. 55, pages 4699-4704, September 15, 1995.	
		Machide, et al., "Effective of Nucleosides on Interferon Production and Development of Antiviral State Induced by Poly I-Poly C", Microbiol. Immunol. Vol. 23 (7) pages 843-850, 1979.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/068 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet 2 of 10	Attorney Docket Number	18003	

NON PATENT PUBLICATIONS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Tran, et al., "Cellular Commitment to Oncogene-Induced Transformation or Apoptosis is Dependent on the Transcription Factor IRF-1", Cell, Vol. 77, pages 629-639, June 17, 1994.	
		Pratt, et al., "Will a Twist of Viral Fate Lead to a New Cancer Treatment?", Science, Vol. 274, Pages 342-343, October 18, 1996.	
		Bischoff, et al., "An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor Cells", Science, Vol. 274, pages 373-376, October 18, 1996.	
		Andersson, et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors", Proc. Natl. Acad. Sci. USA, Vol. 93, pages 11319-11324, October 1996, Colloquium Paper	
		Saito, et al., "Retroviral Vector-mediated Lymphokine Gene Transfer into Human Renal Cancer Cells", Cancer Research, 52, pages 6229-6236, November 1992.	
		Buller, et al., "Cell Proliferative Response to Vaccinia Virus Is Mediated by VGF", Virology, Vol. 164, pages 182-192, 1988.	
		Chiu, et al., "Functional Inactivation of the Large Subunit of Ribonucleotide Reductase Encoded by Vaccinia Virus Is Associated with Reduced Virulence in Vero", Virology, Vol. 174, pages 625-629, 1990.	
		Restifo, et al., "A Nonimmunogenic Sarcoma Transduced with the cDNA for Interferon (Elicits CD8+ T Cells against the Wild-type Tumor...Presentation Capability", The Journal of Experimental Medicine, Vol. 175, pages 1423-1431, June 1992.	
		Buller, et al., "Decreased Virulence of Recombinant Vaccinia Virus Expression Vectors is Associated with a Thymidine Kinase-Negative Phenotype", Nature, Vol. 347, pages 813-815, October 31, 1985	
		Haines, et al., "Correlation of the expression of double-stranded RNA-dependent protein kinase (p68) with differentiation in head and neck squamous cell carcinoma", Virchows Archiv B Cell Pathology, Vol. 63, pages 289-295, 1993	
		James, et al., "Chromosome 9 Deletion Mapping Reveals Interferon x and Interferon B-1 Gene Deletions in Human Gliat Tumors", Cancer Research, Vol. 51, pages 1684-1688, March 15, 1991.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
		Attorney Docket Number	18003
Sheet 3	of 10		

NON PATENT PUBLICATIONS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		<u>Arroyo, et al., "Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon x in a murine hepatic metastasis model", Cancer Immunology Immunotherapy, Vol. 31, pages 565-644, 1990.</u>	
		<u>Zheng, et al., "High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus", Cancer Gene Therapy Vol. 1, No. 1, pages 5-13, 1994.</u>	
		<u>North, et al., "Cloning, expression, and cellular localization of the oncogenic 58-kDa inhibitor of the RNA-activated human and mouse protein kinase", Gene, Vol. 176, pages 161-168, 1996.</u>	
		<u>Barber, et al., "The 58-kDa inhibitor of the interferon-induced double-stranded RNA-activated protein kinases is tetratricopeptide repeat protein with oncogenic properties", Proc. Natl. Acad. Sci. USA, Vol. 91, pages 4278-4282, May 1994.</u>	
		<u>Matthews, et al., "Adenovirus Virus Associated RNA and Translation Control", Journal of Virology, Vol. 65, No. 11, pages 5657-5662, Nov. 1991.</u>	
		<u>Irani, et al., "Inhibitory activity for the interferon-induced protein kinase is associated with the reovirus serotype...protein", Proc. Natl. Acad. Sci. USA, Vol. 85, pages 7887-7891, November 1988.</u>	
		<u>Tanaka, et al., "Immunotherapy of Vaccinia Colon Oncolysate Prepared with Interleukin-2 Gene-Encoded Vaccinia Virus and Interferon X Increase the Survival of Mice Bearing Syngeneic Colon Adenocarcinoma", Journal of Immunotherapy, Vol. 16, No. 4, Pages 283-293, 1994.</u>	
		<u>Cserrny, et al., "Attenuated Veterinary Virus Vaccine for the Treatment of Cancer", Cancer Detection and Prevention, Vol 17, No. 6, pages 619-627, 1993.</u>	
		<u>Geisler, et al., "Newcastle Disease Virus as an Antineoplastic Agent", Cancer, Vol. 18, No. 7, pages 863-868, July 1965.</u>	
		<u>Schimmacher, et al., "Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy", Institut für Immunologie und Genetik am Deutschen Krebsforschungszentrum, 6900 Heidelberg, Germany, pages 19-49, March 13, 1986.</u>	
		<u>Lorenz, et al., "Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor-α and Augmentation of Its Cytotoxicity", Journal of the National Cancer Institute, Vol. 80, No. 16, pages 1305-1312, October 19, 1988.</u>	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4

of 10

Complete if Known

Application Number	09/664,444
Filing Date	September 18, 2000
First Named Inventor	John C. Bell
Group Art Unit	1645
Examiner Name	Robert A. Zeman
Attorney Docket Number	18003

NON PATENT PUBLICATIONS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Reichman, et al., "Newcastle Disease Virus Selectively Kills Human Tumor Cells", Journal of Surgical Research, Vol 52, pages 448-453, 1992.	
		Ellon, et al., "Contribution of Antiviral Immunity to Oncolysis by Newcastle Disease Virus in a Murine Lymphoma", Journal of the National Cancer Institute, Vol. 39, No. 6, December 1967.	
		Bawden, et al., "Immune Responses in Mice to Tumor Challenge After Immunization with Newcastle Disease Virus-Infected or X-Irradiated Tumor Cells or Cell-Free Viruses", Int. Journal of Cancer, Vol. 11, pages 212-223, 1973.	
		Shonham, et al., "Augmentation of Tumor Cell Immunogenicity by Viruses - An Approach to Specific Immunotherapy of Cancer", Nat. Immun. Cell Growth Regul., Vol. 9, pages 165-172, 1990.	
		Hart, et al., "Role of Interferon in the Anti-Melanoma Effects of Poly(I), Poly(C) and Newcastle Disease Virus", Nature New Biology, Vol. 245, No. 147, pages 226-230, October 24, 1973.	
		Silkovits, et al., "New Developments in the Virus Therapy of Cancer: A Historical Review", Intervirology, Vol. 36, pages 193-214, 1993.	
		Murray, et al., "Viral Oncolysate in the Management of Malignant Melanoma", Cancer, Vol. 40, No. 2, pages 680-686, August 1977.	
		Casser, "A Phase II Study on the Postsurgical Management of Stage Malignant Melanoma with a Newcastle Disease Virus Oncolysate", Cancer, Vol. 69, pages 856-860, September 1, 1983.	
		Casser, "A Ten Year Follow-Up on Stage II Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus Oncolysate", Med. Oncol. & Tumor Pharmacother., Vol. 9, No. 4, pages 169-171, 1992.	
		Böhle, et al., "Postoperative Active Specific Immunization in Colorectal Cancer Patients with Virus-Modified Autologous Tumor-Cell Vaccine", Cancer, Vol. 66, No. 7, pages 4547-4553, October 1, 1990.	
		Eaton, et al., "Autoimmunity Induced by Injection of Virus-Modified Cell Membrane Antigens in Syngeneic Mice", Infection and Immunity, Vol. 15, No. 1, pages 609-618, January 1977.	

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/06B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet 5 of 10	Attorney Docket Number	18003	

NON PATENT PUBLICATIONS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Whelock, et al., "Observation on the Repeated Administration of Viruses to a Patient with Acute Leukemia", The New England Journal of Medicine, Vol. 274, No. 13, pages 645-651, September 24, 1964.	
		Century, "Viruses in the Treatment of Cancer", The Lancet, page 625, October 9, 1971.	
		Kenney, et al., "Viruses as Oncolytic Agents: A New Age for "Therapeutic" Viruses?", JNCL Editorial Issue 16, pages 1-3, June 20, 1997.	
		Rodriguez, et al., "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN708: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells", Cancer Research, Vol. 57, pages 2559-2563, July 1, 1997.	
		Martore, "New Treatment Approach for Malignant Brain Tumors Developed at Georgetown", Georgetown University Medical Center, pages 1-6, October 1995.	
		Mineta, et al., "Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas", Nature Medicine, Vol. 1, No. 9, pages 906-912, September 1995.	
		Zhenxiang, et al., "Studies on Viral Immunotherapy of Ascitic Tumors in Mice. I. Results of Treatment on Viruses of Ehrlich and S180 Ascitic Tumor Cells", ACTA Academiae Medicine Sinicae, Vol. 6, No. 3, June 1984.	
		Garry, et al., "Phase I Trial of Intratumoral Injection with an E1B-attenuated adenovirus, ONYX-015, in patients with recurrent p53(+/-) head and neck cancer", Proceedings of ASCO, Vol. 16, page 433a, 1997. Abstract 1362.	
		Kim, et al., "ONYX-015, A selectively replicating adenovirus, has antitumoral activity following IV administration alone and in combination with chemotherapy", Proceedings of ASCO, Vol. 16, page 433a, 1997. Abstract 1564.	
		Izbicka, et al., "Effects of ONYX adenovirus preparations on human tumor colony forming units", Proceedings of ASCO, Vol. 16, page 433a, 1997. Abstract 1664.	
		Kim, et al., "ONYX-015 selectively replicates in and lyses cells lacking functional p53", Proceedings for the American Association for Cancer Research, Vol. 37, page 352, March 1996. Abstract 2400.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet 6 of 10	Attorney Docket Number	18003	

NON PATENT PUBLICATIONS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Field, et al., "The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice", J. Hyg., Camb., Vol. 81, pages 267-277, 1978.	
		Springer, et al., "Attenuated reovirus type 3 strains generated by selection of haemagglutinin antigenic variants", Nature, Vol. 297, pages 66-70, May 6, 1982.	
		Goldstein, et al., "Factor(s) Presented in Herpes Simplex Virus Type 1-Infected Cells Can Compensate for the Loss of the Large Subunit of the Viral Ribonucleic Acid Reductase: Characterization of an ICP6 Deletion Mutant", Virology, Vol. 166, pages 41-51, 1988.	
		Perkus, et al., "Detection of 55 Open Reading Frames from the Termini of Vaccinia Virus", Virology, Vol. 180, pages 406-410, 1991.	
		Meignier, et al., "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (Aotus trivirgatus)", The Journal of Infectious Disease, Vol. 162, pages 313-312, 1990.	
		Hughes, et al., "Vaccinia Virus Encodes an Active Thymidylate Kinase that Complements a cdc8 Mutant of Saccharomyces cerevisiae", Journal of Biological Chemistry, Vol. 266, No. 30, pages 20103-20109, October 25, 1991.	
		Kerr, et al., "Vaccine DNA ligase complements Saccharomyces cerevisiae cdc9, localizes in cytoplasmic factories and affects virulence and virus sensitivity to DNA damaging agents", The EMBO Journal, Vol. 10, No. 13, pages 4343-4350, 1991.	
		Clark, et al., "Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a Predominantly Serotype 1 Rotavirus Season", Journal of Infectious Diseases, Vol. 158, No. 3, pages 570-587, September 1988.	
		Takarup, et al., "Simultaneous Administration of Live, Enteric-Coated Adenovirus Types 4, 7, and 21 Vaccines: Safety and Immunogenicity", Journal of Infectious Diseases, Vol. 140, No. 1, pages 48-53, July 1979.	
		Taylor, et al., "Virus-Induced Regression of Tumor Growth", Journal of the National Cancer Institute, Vol. 44, pages 515-519, March 1970.	
		Beebe, et al., "Host-Range Restriction of Vaccinia Virus E3L-Specific Deletion Mutants", Virus Genes, Vol. 12, No. 1, pages 89-94, 1996.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (PTO/SB/088) of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet 7 of 10	Attorney Docket Number	18003	

NON PATENT PUBLICATIONS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Howard, et al., "Herpesvirus-Mediated Gene Transfer of the Human...Gene: A Therapy for Cancer", Annals New York Academy of Sciences, Duke University Medical Center, pages 167-187.	
		Stuskin, et al., "US Dept. of Health, Education & Welfare, N.I.H., National Institute of Allergy and Infectious Disease, and N.C.I., Bethesda, MD., "Viral Agents Oncolytic for Human Tumors in Heterologous Host: Oncolytic Effect of Coxsackie B. Viruses, pages 309-316, October 20, 1956"	
		Bleming, et al., "Regression of Burkitt's Lymphoma...Association with Measles Infection" The Lancet, pages 105-106, July 10, 1971.	
		Pasquinucci, et al., "Possible Effect of Measles on Leukemia", The Lancet, page 136, January 16, 1971.	
		Gross, "Measles and Leukemia", The Lancet, Pages 987-990, February 20, 1974.	
		Shieff, "Therapeutic effects of bovine enterovirus infection on rabbits with experimentally induced adult T cell leukaemia", Journal of General Virology, Vol. 72, pages 2031-2034, 1991.	
		Faberg, et al., "Strain Variation and Nuclear Association of Newcastle Disease Virus Matrix Protein", Journal of Virology, Vol. 62, No. 2, pages 588-593, February 1988.	
		Rozdzinski, et al., "The Use of APC3 Virus as a Cancericidal Agent", Cancer, Vol. 10, Pages 577-580, May-June 1957.	
		Smith, et al., "Studies on the Use of Viruses in the Treatment of Carcinoma of the Cervix", Cancer, Vol. 9, pages 1211-1218, November-December 1966.	
		Rukavishnikova, et al., "Gene Immunological Mechanisms of the Influenza Virus Antitumour Effect", Acta Virol., Vol. 20, pages 387-394, 1976	
		Venne, et al., "Gene therapy: promises, problem and prospects", Nature, Vol. 389, pages 239-242, September 18, 1997.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORM/S TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1645
		Examiner Name	Robert A. Zeman
Sheet 8 of 10	Attorney Docket Number	18003	

NON PATENT PUBLICATIONS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RAZ/		Kalvakolani, et al., "Differentiation-dependent activation of interferon-stimulated gene factors and transcription factor NF-kB in mouse embryonal carcinoma cells", Proc. Natl. Acad. Sci. USA, Vol. 90, pages 3167-3171, April 1993.	
/RAZ/		Foy, et al., "In Vivo CD40-gp39 Interactolins are Essential for Thymus-Dependent Humoral Immunity. II. Prolonged Suppression of the Humoral Immune Response by an Antibody to the Ligand for CD40-gp39", J. Exp. Med., Vol. 178, pages 1567-1575, November 1993.	
/RAZ/		Blaese, et al., "In situ Delivery of Suicide Genes for Cancer Treatment", European Journal of Cancer, Vol. 30A, No. 8, Pages 1190-1193, 1994.	
/RAZ/		Zhang, et al., "Gene Therapy with an adeno-associated virus carrying an Interferon gene results in tumor growth suppression and regression", Cancer Gene Therapy, Vol. 3, No. 1, pages 31-38, 1996.	
/RAZ/		Peplinski, et al., "Prevention of Murine Breast Cancer by Vaccination with Tumor Cells Modified by Cytokine-Producing Recombinant Vaccinia Viruses", Annals of Surgical Oncology, Vol. 3, No. 1, pages 15-23.	
/RAZ/		Cotran, et al., "Kinetics of Tumor Cell Growth", Robbins Pathologic Basis of Disease, 4th Edition, page 251.	
/RAZ/		Schloer, et al., "Relationship of Plaque Size and Virulence for Chickens for 14 Representative Newcastle Disease Virus Strains", Journal of Virology, Vol. 2, No. 1, Pages 40-47, January 1968.	
/RAZ/		Tait, et al., "A Phase I Trial of Retroviral BRCA1sv Gene Therapy in Ovarian Cancer", Clinical Cancer Research, Vol. 3, pages 1959-1968, November 1997.	
/RAZ/		Martuza, et al., "Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant", Science, Vol. 252, pages 854-855, May 10, 1991.	
/RAZ/		Hanson, et al., "Identification of Vaccine Strains of Newcastle Disease Virus", Science, Vol. 122, pages 156-157, July 22, 1955.	
/RAZ/		Chambers, et al., "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma", Proc. Natl. Acad. Sci. USA, Vol. 92, pages 1411-1415, February 1995.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002, OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/664,444
		Filing Date	September 18, 2000
		First Named Inventor	John C. Bell
		Group Art Unit	1845
		Examiner Name	Robert A. Zeman
		Attorney Docket Number	18003
Sheet 9	of 10		

NON PATENT PUBLICATIONS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Asada, "Treatment of Human Cancer with Mumps Virus", Cancer, Vol. 34, pages 1907-1928, December 1974.	
		Stevens, "Chapter 14 Biologic Therapy with Interferon-x and B: Preclinical Studies", Biologic Therapy of Cancer: Principles and Practice, pages 347-364	
		Stemon, et al., "Effect of Neuraminidase Pretreatment on the Susceptibility of Normal and Transformed Mammalian Cells to Bovine Enterovirus 261", Virology, Vol. 245, pages 319-320, October 12, 1973.	
		Joklik, "Interferons", Chapter 10, Second Edition, pages 388-449, 1990.	
		Schell, et al., "Construction of a Novel Virus that Targets HIV-1 Infected Cells and Controls HIV-1 Infection", Cell, Vol. 90, pages 849-857, September 5, 1997.	
		Kitchener, et al., "Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines", World J. Urol., Vol. 15, pages 474-473, 1995.	
		Murphy, et al., "Virus Taxonomy", Virology, Second Edition, Chapter 2, pages 9-36, 1990.	
		Carter, "Viruses in the Treatment of Cancer", The Lancet, page 926, October 0, 1971.	
		Haslro, et al., "The Preferential Cytotoxicity of Reovirus for Certain Transformed Cell Lines", Archives of Virology, Vol. 54, pages 307-315, 1977.	
		Zhang, "Attenuated newcastle disease virus for induction of interferons to combat neoplasm or viral disease, Database CAPUS, on CD-ROM Columbus (OH): Chemical Abstract Sence, DN 116: 104333, CN 1054192A, Abstract, April 9, 1991.	
		Gresser, et al., "Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice Inoculated with RC19 Tumor Cells", Nature, Vol. 223, pages 844-845, August 1969.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

